The University of Chicago Header Logo

Connection

Rudolph Navari to Humans

Back to Details
This is a "connection" page, showing publications Rudolph Navari has written about Humans.
Rudolph Navari
Connection Strength
1.094
Humans
  1. Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602). Oncologist. 2023 08 03; 28(8):722-729.
    View in: PubMed
    Score: 0.029
  2. Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Adv Ther. 2023 07; 40(7):3217-3226.
    View in: PubMed
    Score: 0.029
  3. Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles. Oncologist. 2023 03 17; 28(3):208-213.
    View in: PubMed
    Score: 0.028
  4. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol. 2021 Aug; 17(23):3027-3035.
    View in: PubMed
    Score: 0.025
  5. Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. Oncologist. 2021 04; 26(4):325-331.
    View in: PubMed
    Score: 0.024
  6. The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting-Reply. JAMA Oncol. 2020 11 01; 6(11):1812-1813.
    View in: PubMed
    Score: 0.024
  7. Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. Future Oncol. 2020 Aug; 16(24):1863-1872.
    View in: PubMed
    Score: 0.024
  8. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial. JAMA Oncol. 2020 06 01; 6(6):895-899.
    View in: PubMed
    Score: 0.023
  9. What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy. J Natl Compr Canc Netw. 2020 06; 18(6):676-681.
    View in: PubMed
    Score: 0.023
  10. Olanzapine is an effective antiemetic agent. Ann Palliat Med. 2020 05; 9(3):628-630.
    View in: PubMed
    Score: 0.023
  11. Nausea and Vomiting in Advanced Cancer. Curr Treat Options Oncol. 2020 02 05; 21(2):14.
    View in: PubMed
    Score: 0.023
  12. Impact of Addition of Carboplatin AUC = 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care. JCO Oncol Pract. 2020 02; 16(2):e132-e138.
    View in: PubMed
    Score: 0.023
  13. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf. 2020 Feb; 19(2):205-210.
    View in: PubMed
    Score: 0.023
  14. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. Expert Opin Drug Saf. 2019 Dec; 18(12):1127-1132.
    View in: PubMed
    Score: 0.022
  15. HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis. Future Oncol. 2019 Jan; 15(3):241-255.
    View in: PubMed
    Score: 0.021
  16. Safety of Polysorbate 80 in the Oncology Setting. Adv Ther. 2018 Jun; 35(6):754-767.
    View in: PubMed
    Score: 0.020
  17. Managing Nausea and Vomiting in Patients With Cancer: What Works. Oncology (Williston Park). 2018 03 15; 32(3):121-5, 131, 136.
    View in: PubMed
    Score: 0.020
  18. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. Paediatr Drugs. 2017 Jun; 19(3):213-222.
    View in: PubMed
    Score: 0.019
  19. Olanzapine for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 10 06; 375(14):1396.
    View in: PubMed
    Score: 0.018
  20. Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting. Drugs Today (Barc). 2016 Aug; 52(8):431-438.
    View in: PubMed
    Score: 0.018
  21. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Jul 14; 375(2):134-42.
    View in: PubMed
    Score: 0.018
  22. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Apr 07; 374(14):1356-67.
    View in: PubMed
    Score: 0.018
  23. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf. 2016; 15(3):343-56.
    View in: PubMed
    Score: 0.017
  24. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2015; 15(10):1127-33.
    View in: PubMed
    Score: 0.017
  25. Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting. Biomed Res Int. 2015; 2015:595894.
    View in: PubMed
    Score: 0.017
  26. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015 Sep; 16(9):1079-1089.
    View in: PubMed
    Score: 0.017
  27. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta. 2015 Oct; 1848(10 Pt B):2738-46.
    View in: PubMed
    Score: 0.016
  28. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther. 2015; 9:155-61.
    View in: PubMed
    Score: 0.016
  29. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014 Dec; 15(17):2599-608.
    View in: PubMed
    Score: 0.016
  30. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2014 Jan 05; 722:180-6.
    View in: PubMed
    Score: 0.015
  31. The current status of the use of palonosetron. Expert Opin Pharmacother. 2013 Jul; 14(10):1281-4.
    View in: PubMed
    Score: 0.014
  32. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents. Drugs. 2013 Mar; 73(3):249-62.
    View in: PubMed
    Score: 0.014
  33. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013 Jun; 21(6):1655-63.
    View in: PubMed
    Score: 0.014
  34. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011 Sep-Oct; 9(5):188-95.
    View in: PubMed
    Score: 0.013
  35. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol. 2010 Jul; 6(7):1073-84.
    View in: PubMed
    Score: 0.012
  36. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opin Drug Metab Toxicol. 2009 Dec; 5(12):1577-86.
    View in: PubMed
    Score: 0.011
  37. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer. 2010 Aug; 18(8):951-6.
    View in: PubMed
    Score: 0.011
  38. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother. 2009 Mar; 10(4):629-44.
    View in: PubMed
    Score: 0.011
  39. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs. 2009; 69(5):515-33.
    View in: PubMed
    Score: 0.011
  40. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008 Nov; 8(11):1733-42.
    View in: PubMed
    Score: 0.011
  41. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities. Curr Opin Investig Drugs. 2008 Jul; 9(7):774-85.
    View in: PubMed
    Score: 0.010
  42. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008 Nov; 112(1):197-201.
    View in: PubMed
    Score: 0.010
  43. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007 Dec; 16(12):1977-85.
    View in: PubMed
    Score: 0.010
  44. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007 Nov; 15(11):1285.
    View in: PubMed
    Score: 0.009
  45. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw. 2007 Jan; 5(1):51-9.
    View in: PubMed
    Score: 0.009
  46. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol. 2006 Oct; 2(5):591-602.
    View in: PubMed
    Score: 0.009
  47. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct; 12(5):341-7.
    View in: PubMed
    Score: 0.009
  48. Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar; 11(1):137-51.
    View in: PubMed
    Score: 0.009
  49. Symptomatic treatment of infections in patients with advanced cancer receiving hospice care. J Pain Symptom Manage. 2005 Aug; 30(2):175-82.
    View in: PubMed
    Score: 0.008
  50. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer. 2005 Jul; 13(7):529-34.
    View in: PubMed
    Score: 0.008
  51. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2004 Oct; 4(5):715-24.
    View in: PubMed
    Score: 0.008
  52. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials. Cancer Invest. 2004; 22(4):569-76.
    View in: PubMed
    Score: 0.008
  53. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2023 Dec 18; 32(1):36.
    View in: PubMed
    Score: 0.008
  54. Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis. Support Care Cancer. 2023 Oct 25; 31(12):654.
    View in: PubMed
    Score: 0.007
  55. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother. 2003 Sep; 37(9):1276-86.
    View in: PubMed
    Score: 0.007
  56. Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med. 2023 08; 12(15):15769-15776.
    View in: PubMed
    Score: 0.007
  57. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. J Support Oncol. 2003 Jul-Aug; 1(2):89-103.
    View in: PubMed
    Score: 0.007
  58. Antimicrobial use in patients with advanced cancer receiving hospice care. J Pain Symptom Manage. 2003 May; 25(5):438-43.
    View in: PubMed
    Score: 0.007
  59. Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Support Care Cancer. 2022 Feb; 30(2):1015-1018.
    View in: PubMed
    Score: 0.007
  60. International study in premedical education. Acad Med. 2001 Nov; 76(11):1158.
    View in: PubMed
    Score: 0.006
  61. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 Jul; 29(7):3439-3459.
    View in: PubMed
    Score: 0.006
  62. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients. Support Care Cancer. 2021 Aug; 29(8):4269-4275.
    View in: PubMed
    Score: 0.006
  63. Preferences of patients with advanced cancer for hospice care. JAMA. 2000 Nov 15; 284(19):2449.
    View in: PubMed
    Score: 0.006
  64. Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. Crit Rev Oncol Hematol. 2021 Jan; 157:103143.
    View in: PubMed
    Score: 0.006
  65. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. Oncologist. 2020 03; 25(3):e589-e597.
    View in: PubMed
    Score: 0.006
  66. A prisoner with chronic myeloid leukemia. Bone Marrow Transplant. 1999 Nov; 24(9):1037-9.
    View in: PubMed
    Score: 0.006
  67. Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. Crit Rev Oncol Hematol. 2019 Oct; 142:164-186.
    View in: PubMed
    Score: 0.006
  68. Use of placebos in delayed-emesis studies. J Clin Oncol. 1999 May; 17(5):1648-50.
    View in: PubMed
    Score: 0.005
  69. Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE). J Geriatr Oncol. 2020 03; 11(2):270-273.
    View in: PubMed
    Score: 0.005
  70. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999 Jan 21; 340(3):190-5.
    View in: PubMed
    Score: 0.005
  71. Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom: A Pilot Study. Invest Radiol. 2019 01; 54(1):16-22.
    View in: PubMed
    Score: 0.005
  72. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018 07 01; 29(7):1535-1540.
    View in: PubMed
    Score: 0.005
  73. Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer. 2018 Aug; 26(8):2519-2549.
    View in: PubMed
    Score: 0.005
  74. Thalidomide: Rebirth of a Gestational Antiemetic? J Clin Oncol. 2017 11 01; 35(31):3523-3524.
    View in: PubMed
    Score: 0.005
  75. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations. Drug Des Devel Ther. 2017; 11:2621-2629.
    View in: PubMed
    Score: 0.005
  76. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2017 01; 25(1):303-308.
    View in: PubMed
    Score: 0.005
  77. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Support Care Cancer. 2017 01; 25(1):85-92.
    View in: PubMed
    Score: 0.005
  78. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 01; 25(1):277-288.
    View in: PubMed
    Score: 0.004
  79. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016 Apr; 57:23-30.
    View in: PubMed
    Score: 0.004
  80. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer. 2016 May; 24(5):2381-2392.
    View in: PubMed
    Score: 0.004
  81. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Support Care Cancer. 2016 Feb; 24(2):1001-1008.
    View in: PubMed
    Score: 0.004
  82. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol. 1995 Sep; 13(9):2408-16.
    View in: PubMed
    Score: 0.004
  83. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 2015 Sep; 16(9):1071-1078.
    View in: PubMed
    Score: 0.004
  84. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol. 1995 May; 13(5):1242-8.
    View in: PubMed
    Score: 0.004
  85. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol. 1994 Oct; 12(10):2204-10.
    View in: PubMed
    Score: 0.004
  86. Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2014 Mar; 12(3 Suppl 9):1-14; quiz 15.
    View in: PubMed
    Score: 0.004
  87. Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. Cancer. 1993 Jul 15; 72(2):583-6.
    View in: PubMed
    Score: 0.004
  88. Blood component therapy in trauma guided with the utilization of the perfusionist and thromboelastography. J Extra Corpor Technol. 2011 Sep; 43(3):162-7.
    View in: PubMed
    Score: 0.003
  89. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J Clin Endocrinol Metab. 1991 Jul; 73(1):99-106.
    View in: PubMed
    Score: 0.003
  90. An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia. Blood. 2011 Jan 06; 117(1):283-9.
    View in: PubMed
    Score: 0.003
  91. Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy. J Clin Oncol. 1989 Jul; 7(7):943-6.
    View in: PubMed
    Score: 0.003
  92. Hypothermia. Ala J Med Sci. 1984 Oct; 21(4):374-81.
    View in: PubMed
    Score: 0.002
  93. Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants. Am J Med. 1984 Apr; 76(4):564-72.
    View in: PubMed
    Score: 0.002
  94. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest. 2004; 22(3):383-8.
    View in: PubMed
    Score: 0.002
  95. Mycobacterial infections in marrow transplant patients. Transplantation. 1983 Nov; 36(5):509-13.
    View in: PubMed
    Score: 0.002
  96. Pneumatosis cystoides intestinalis following allogeneic marrow transplantation. Transplant Proc. 1983 Jun; 15(2):1720-4.
    View in: PubMed
    Score: 0.002
  97. The peripheral blood smear in heat stroke. An aid to diagnosis. Ala J Med Sci. 1983 Apr; 20(2):137-40.
    View in: PubMed
    Score: 0.002
  98. Bone marrow necrosis in acute leukemia. Acta Haematol. 1983; 69(3):158-63.
    View in: PubMed
    Score: 0.002
  99. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002 Jun 01; 94(11):3032-41.
    View in: PubMed
    Score: 0.002
  100. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002 Jan 01; 94(1):25-36.
    View in: PubMed
    Score: 0.002
  101. Renal adenocarcinoma associated with multiple simple cysts. JAMA. 1981 Oct 16; 246(16):1808-9.
    View in: PubMed
    Score: 0.002
  102. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998 Apr; 16(4):1568-73.
    View in: PubMed
    Score: 0.001
  103. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997 Aug; 15(8):2966-73.
    View in: PubMed
    Score: 0.001
  104. Mass transfer properties of gases in fluorocarbons. Res Exp Med (Berl). 1977 Jun 29; 170(2):169-80.
    View in: PubMed
    Score: 0.001
  105. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol. 1997 May; 15(5):2135-8.
    View in: PubMed
    Score: 0.001
  106. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol. 1997 Feb; 8(2):181-5.
    View in: PubMed
    Score: 0.001
  107. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer. 1997 Jan; 5(1):31-7.
    View in: PubMed
    Score: 0.001
  108. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. Cancer Invest. 1997; 15(4):297-303.
    View in: PubMed
    Score: 0.001
  109. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. Cancer. 1996 Aug 15; 78(4):789-93.
    View in: PubMed
    Score: 0.001
  110. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol. 1996 Aug; 14(8):2242-9.
    View in: PubMed
    Score: 0.001
  111. Laboratory experiments using nicotine. J Chem Educ. 1974 Nov; 51(11):748-50.
    View in: PubMed
    Score: 0.001
  112. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med. 1994 Sep 12; 154(17):1935-44.
    View in: PubMed
    Score: 0.001
  113. Protein turnover in advanced lung cancer patients. Metabolism. 1993 Mar; 42(3):291-6.
    View in: PubMed
    Score: 0.001
  114. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992 Dec; 10(12):1969-75.
    View in: PubMed
    Score: 0.001
  115. Glucose metabolism in advanced lung cancer patients. Nutrition. 1992 Jul-Aug; 8(4):245-51.
    View in: PubMed
    Score: 0.001
  116. Transport in human plasma. Aerosp Med. 1971 Oct; 42(10):1123-4.
    View in: PubMed
    Score: 0.001
  117. Treatment of marrow graft recipients with thymopentin. Bone Marrow Transplant. 1987 Apr; 1(4):365-71.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.